Edition:
India

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

4.76EUR
16 Oct 2019
Change (% chg)

€-0.01 (-0.21%)
Prev Close
€4.76
Open
€4.80
Day's High
€4.80
Day's Low
€4.73
Volume
31,814
Avg. Vol
56,380
52-wk High
€7.14
52-wk Low
€4.30

Latest Key Developments (Source: Significant Developments)

Nicox Q3 Net Revenue Up At 0.5 Million Euros
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - NICOX SA ::Q3 2019 NET REVENUE OF EUR 0.5 MILLION.POSITIVE TOPLINE RESULTS FROM DOLOMITES PHASE 2 CLINICAL TRIAL OF NCX 470 IN GLAUCOMA.IN Q3 VYZULTA PRESCRIPTIONS EXCEEDED 3,000 PER WEEK FOR FIRST TIME.AS OF SEPTEMBER 30, 2019, THE NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF €17.4 MILLION.NICOX AMENDED ITS BOND FINANCING AGREEMENT WITH KREOS CAPITAL AND DREW DOWN EUR 4 MILLION IN ADDITIONAL DEBT..AS OF SEPTEMBER 30, 2019, THE NICOX GROUP HAD FINANCIAL DEBT OF €7.4 MILLION IN THE FORM OF A BOND FINANCING AGREEMENT WITH KREOS CAPITAL SIGNED IN JANUARY 2019..NICOX MAY DRAW DOWN A FURTHER EUR 3 MILLION OR EUR 8 MILLION ON DECEMBER 31.  Full Article

Nicox Announces Completion Of Enrollment In NCX 470 Phase 2 Clinical Study
Tuesday, 16 Jul 2019 

July 16 (Reuters) - Nicox SA ::PRIMARY ENDPOINT OF STUDY IS MEAN REDUCTION IN DIURNAL IOP AFTER 28 DAYS OF TREATMENT (REMOVES EXTRANEOUS TEXT).REG-NICOX ANNOUNCES COMPLETION OF ENROLLMENT IN NCX 470 PHASE 2 CLINICAL STUDY WITH TOP-LINE RESULTS ON TRACK FOR EARLY 4Q 2019.TOP-LINE DATA OF STUDY ARE EXPECTED EARLY IN Q4 OF THIS YEAR.OVERALL OBJECTIVE IS TO IDENTIFY APPROPRIATE DOSE OF NCX 470 TO BE ADVANCED INTO PHASE 3 CLINICAL STUDIES.  Full Article

Nicox Announces U.S. FDA Acceptance Of Investigational New Drug Application For NCX 4251
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - NICOX SA ::NICOX ANNOUNCES U.S. FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NCX 4251 PHASE 2 TRIAL IN BLEPHARITIS.IND WAS SUBMITTED TO U.S. FDA IN DECEMBER 2018 AHEAD OF TARGET OF Q1 OF 2019.WE LOOK FORWARD TO ANNOUNCING START OF FIRST-IN-HUMAN PHASE 2 CLINICAL TRIAL WHICH IS EXPECTED TO REPORT TOP-LINE RESULTS IN H2 2019.PHASE 2 CLINICAL TRIAL FOR PATIENTS WITH ACUTE EXACERBATIONS OF BLEPHARITIS, WHICH IS EXPECTED TO REPORT TOP-LINE RESULTS IN SECOND HALF OF 2019.  Full Article

Nicox And Ocumension Therapeutics Sign Exclusive License Agreement To Develop And Commercialize NCX 470 In Chinese Market
Monday, 17 Dec 2018 

Dec 17 (Reuters) - NICOX SA ::NICOX AND OCUMENSION THERAPEUTICS SIGN EXCLUSIVE LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE NCX 470 IN THE CHINESE MARKET.NICOX TO POTENTIALLY RECEIVE UP TO EUR 36.25 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONES PAYMENTS.TIERED ROYALTIES FROM 6% TO 12% ON NET SALES OF NCX 470 IN CHINESE MARKET.OCUMENSION RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES IN CHINESE MARKET.ALL DEVELOPMENT ACTIVITIES WILL BE OVERSEEN BY A JOINT DEVELOPMENT COMMITTEE COMPRISING REPRESENTATIVES OF BOTH COMPANIES.UNDER THE TERMS OF THE AGREEMENT, NICOX WILL RECEIVE A FURTHER €2.5 MILLION WHEN NICOX INITIATES PHASE 3 CLINICAL STUDY WITH NCX 470 OUTSIDE THE TERRITORY OF THIS AGREEMENT.OCUMENSION IS EXPECTED TO HAVE TO CONDUCT ADDITIONAL CLINICAL STUDIES FOR THE REGULATORY APPROVAL OF NCX 470 IN THE CHINESE MARKET.  Full Article

Nicox Announces Research Collaboration With Ironwood Pharmaceuticals
Wednesday, 6 Jun 2018 

June 6 (Reuters) - NICOX SA ::REG-NICOX ANNOUNCES RESEARCH COLLABORATION ON NOVEL OPHTHALMIC THERAPEUTICS WITH IRONWOOD PHARMACEUTICALS.EACH COMPANY WILL BE RESPONSIBLE FOR THEIR OWN COSTS ASSOCIATED WITH ACTIVITIES CARRIED OUT AS PART OF COLLABORATION.DEPENDING ON OUTCOME, COS MAY ENTER INTO DISCUSSIONS ON NICOX'S FURTHER DEVELOPMENT OF ANY IDENTIFIED PRODUCT CANDIDATE..  Full Article

Nicox Announces Increase In Royalties From Bausch + Lomb For Vyzulta
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Nicox Sa ::REG-NICOX ANNOUNCES IMPROVED FINANCIAL TERMS FROM BAUSCH + LOMB FOR VYZULTA.‍INCREASE IN ROYALTIES BY 1% ON ANNUAL VYZULTA(TM) GLOBAL SALES REVENUE OVER $300 MILLION​.‍ADDITIONAL $20 MILLION IN POTENTIAL MILESTONES​.‍ROYALTIES WILL NOW BE 10% TO 16% OVER FOUR TIERS​.  Full Article

Nicox Provides 2018 Outlook And 2017 Estimated Financial Results
Tuesday, 6 Mar 2018 

March 6 (Reuters) - NICOX SA ::PROVIDES 2018 OUTLOOK AND 2017 ESTIMATED FINANCIAL RESULTS.ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, U.S. LAUNCH PLANNED BY PARTNER EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON.PIPELINE CANDIDATES MOVING TOWARDS CLINICAL DEVELOPMENT, WITH IND SUBMISSIONS TO THE U.S. FDA PLANNED FOR NCX 470 IN Q3 2018 AND NCX 4251 IN Q1 2019.ESTIMATED CASH POSITION OF €41.4 MILLION AS OF DECEMBER 31, 2017.IN 2018 WE ALSO EXPECT TO MAKE SIGNIFICANT ADVANCES IN OUR NO-DONATING RESEARCH PIPELINE - CEO.  Full Article

Nicox Updates on Drug Development And Outlines 2018 Activities
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - NICOX SA ::RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT.ESTIMATES THAT THE U.S. PATENTS COVERING VYZULTA COULD BE EXTENDED FROM 2025 TO 2030..EXPECTS TO BEGIN RECEIVING ROYALTY REVENUE IN 2018, ALONG WITH POTENTIAL SALES AND DEVELOPMENT MILESTONES PAYMENTS‍​.NCX 470 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018.NCX 4251 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018.  Full Article

Bausch + Lomb and Nicox announces FDA approval of Vyzulta
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc :Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%.Valeant - ‍co's wholly owned subsidiary, Bausch + Lomb and Nicox S.A announced FDA approved NDA for Vyzulta​.  Full Article